About Finesse Solutions
Finesse was founded to bring digital, plug-and-play solutions to life science customers, so as to improve the management of complex bio-process applications. The company's initial focus is on improving sensor, hardware, and software solutions for process control in the biotechnology and pharmaceutical industries.
Finesse Solutions Patents
Finesse Solutions has filed 29 patents.
Biotechnology, Bioreactors, Biological engineering, Fluid dynamics, Membrane technology
Biotechnology, Bioreactors, Biological engineering, Fluid dynamics, Membrane technology
Latest Finesse Solutions News
Jun 8, 2023
" - https://www.reportlinker.com/p06466645/?utm_source=GNW , Eppendorf AG, Corning Corporation, Ferner PLC, Ashai Kasei Corporation, and Finesse Solutions Inc. The global downstream processing market is expected to grow from $23.72 billion in 2022 to $27.19 billion in 2023 at a compound annual growth rate (CAGR) of 14.6%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The downstream processing market is expected to reach $45.13 billion in 2027 at a CAGR of 13.5%. The downstream processing market consists of revenues earned by entities by providing downstream processing services such as cell separation, filtration, product recovery, extraction of products, and more.The market value includes the value of related goods sold by the service provider or included within the service offering. The Downstream processing market also includes sales of small-scale fermenters, pilot-scale fermenters, centrifuges, and membrane filtration systems which are used in providing downstream processing services.Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. Downstream processing refers to the recovery and purification of a drug substance (DS) from natural sources, such as animal or bacterial cells. It outlines the sequence of steps necessary to create a pure and homogenous protein product from biological components such as cells, tissue culture fluid, or plant tissues. North America was the largest region in the downstream processing market in 2022.Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the downstream processing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The main types of products used in downstream processing are centrifuges, dryers, chromatography systems, filters, evaporators, and others, with various types of techniques involved, including purification techniques, solid-liquid separation, and clarification or concentration.Centrifuges refer to a device that uses centrifugal force to separate materials with different densities, remove moisture, or simulate the effects of gravity. It is used in several applications, such as monoclonal antibody production, vaccine production, insulin production, immunoglobulin production, erythropoietin production, and others. The increasing healthcare expenditure is expected to propel the growth of the downstream processing market going forward.Healthcare expenditure refers to all expenditures for the provision of health services, family planning activities, nutrition activities, and emergency aid designated for health. Downstream processing.Increasing expenditure would boost the sales of downstream processing as it helps in the extraction of a drug substance (DS) from natural sources, such as bacterial or animal cells, and the subsequent purification of the drug substance. For instance, in March 2022, according to the 2021–2030 National Health Expenditure (NHE) report published by the Centers for Medicare & Medicaid Services, a US-based Department of Health and Human Services department, the annual increase in national health spending was predicted to average 5.1% between 2021 and 2030, reaching approximately $6.8 trillion by 2030. Additionally, throughout the period 2021–2030, Medicare expenditures are expected to expand at a 7.2% annual rate, while Medicaid spending is expected to grow at a 5.6% annual rate. Therefore, the increasing healthcare expenditure is driving the growth of the downstream processing market. Product innovations are the key trends gaining popularity in the downstream processing market.Major companies operating in the downstream processing market are focused on developing new technological solutions to strengthen their position in the market. For instance, in September 2022, Tosoh Bioscience LLC, a US-based global chemical and specialty materials company, launched the Octave BIO Multi-Column Chromatography (MCC) system, a holistic multi-column chromatography solution for downstream process intensification.It is an advanced multi-column chromatography system for process development and proof of concept that was specifically created for the intensification of biomolecule purification processes. Wide-ranging requirements can be accommodated by the special modular design, which also makes it possible to take advantage of MCC’s resin and buffer cost savings and other real advantages. In January 2023, Astea Bio separations, a UK-based provider of bio separation and purification technologies, acquired Delta Precision Ltd. for an undisclosed amount. This acquisition will enable Astea Bio separations to strengthen and supplement its current portfolio of bioprocessing resins, reusable columns, and prepacked single-use columns by adding a broad range of high-performance chromatography columns for biomanufacturing. Delta Precision Ltd. is a UK-based manufacturer of advanced chromatography columns, and it produces products for various applications, including protein purification, vaccine production, and drug development. The countries covered in the downstream processing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The downstream processing market research report is one of a series of new reports that provides downstream processing market statistics, including downstream processing industry global market size, regional shares, competitors with a downstream processing market share, detailed downstream processing market segments, market trends and opportunities, and any further data you may need to thrive in the downstream processing industry. This downstream processing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Finesse Solutions Frequently Asked Questions (FAQ)
When was Finesse Solutions founded?
Finesse Solutions was founded in 2005.
Where is Finesse Solutions's headquarters?
Finesse Solutions's headquarters is located at 71 Daggett Dr, San Jose.
What is Finesse Solutions's latest funding round?
Finesse Solutions's latest funding round is Acquired.
Who are the investors of Finesse Solutions?
Investors of Finesse Solutions include Thermo Fisher Scientific.
Who are Finesse Solutions's competitors?
Competitors of Finesse Solutions include Axxam, MOgene LC, Bloomage BioTech, Algaen, LS9 and 7 more.
Compare Finesse Solutions to Competitors
Triacle Biocomputing Is A Software Development Company Serving The Life Science, Biomedical And Biotechnology Sector.
Hylobates Consulting s.r.l. is company that aims to provide consulting in risk and safety. The company collaborate with businesses in the food, cosmetic, food supplement and biotechnology industries so that they can achieve high margins of safety for their products. The company's services are based on the best and latest available science and technology, on the company's actual experience and oriented to fulfilling the needs of the company's customers. The company specialize in the HACCP method, with a set of consulting services, that includes allergen management. Other services include risk analyses for foodborne hazards.nIn the area of biosafety, the company assess and analyze risks for GMOs and GMMs, the company design sampling plans and strategies to control or prevent cross-contamination and for coexistence.
MOgene LC is a company that focuses on providing genomic services, operating within the biopharma and agritech industries. The company offers a range of services including genomic sequencing and bioinformatics, aimed at delivering precise research and clinical insights. Its primary customer segments include the agriculture, pharmaceutical, and industrial biotech industries. It was founded in 2004 and is based in St. Louis, Missouri.
Oceanit is a 'Mind to Market' company that focuses on creating disruptive technology from fundamental science across various sectors such as aerospace, healthcare, energy, and industrial/consumer technologies. The company offers a range of services including engineering consulting, information systems consulting, and management consulting, with a focus on creating innovative solutions through scientific research and design thinking. Oceanit primarily serves sectors such as the energy industry, healthcare sector, aerospace and defense industry, and the industrial and consumer technology industry. It was founded in 2002 and is based in Honolulu, Hawaii.
deltaDOT Ltd is a life science company that is developing and commercialising enabling technologies for the separation and analysis of biomolecules. It was founded in 2000 and is a spin out from Imperial College of Science, Technology and Medicine, London. deltaDOT's core label free analysis technology, coupled with software algorithms, forms the technical basis of its products. This label free technology aims to enable higher quality and faster separations compared to existing technologies. The increased performance aims to enable the direct monitoring of unlabelled biomolecules, reducing the cost per analysis compared to conventional methods. deltaDOT addresses biomolecular separation applications within pharmaceutical, biotechnology, biodefence, food and drink quality, forensic science, diagnostic and academic markets. The London Technology Fund participated in a funding round of £6m in March 2006.
Cambridge Biostability Limited (CBL) is a UK Biotechnology Company based on the Cambridge Science Park.